Abbott Hit With 5 AndroGel Suits In FDA Probe's Wake

Law360, New York (February 5, 2014, 7:14 PM EST) -- Abbott Laboratories Inc. and AbbVie Inc. downplayed the stroke and heart attack risks associated with testosterone replacement treatment AndroGel, according to five lawsuits filed in Illinois federal court Tuesday, just days after the U.S. Food and Drug Administration began investigating the treatment.

The two drugmakers have engaged in an extensive advertising campaign about low testosterone, telling consumers that the natural effects of aging in men, such as listlessness and weight gain, were actually symptoms of the condition that could be treated with their products, according to the lawsuits, brought separately by five plaintiffs.

“What consumers received, however, were not safe drugs,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!